A Phase III study involving 109 male participants with hemophilia A and inhibitors showed that once-weekly subcutaneous prophylactic administration of an investigational bispecific humanized monoclonal antibody (emicizumab; ACE910) was associated with a significantly lower rate of bleeding events than no prophylaxis.
The U.S. Department of Health and Human Services has proposed 2018 updates to the Medicare hospital outpatient prospective payment system to decrease Medicare Part B payments to hospitals for 340B drugs by almost 30 percent.
The U.S. Senate passed the Creating High-Quality Results and Outcomes Necessary to Improve Chronic(CHRONIC) Care Act of 2017, which aims to improve care for seniors with chronic conditions.
The U.S. Food and Drug Administration has approved Agios Pharmaceuticals’ Idhifa (enasidenib) to treat acute myelogenous leukemia.
The U.S. Food and Drug Administration has approved CSL Behring’s Haegarda (C1 esterase inhibitor subcutaneous [human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients.
The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
CSL Behring has awarded three U.S. bleeding disorder patient organizations Local Empowerment for Advocacy Development (LEAD) grants to help them ensure patients’ voices continue to be heard in their state capitals on legislative and public policy issues.
The House Energy and Commerce Committee and the Senate Finance Committee passed bills to extend for five years the federal funding forChildren’s Health Insurance Program.
The U.S. Food and Drug Administration has approved AbbieVie Inc.’s Mavyret (glecaprevir and pibrentasvir) to treat adults with certain types of hepatitis C.
Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.
New rules issued by the U.S. Department of Health and Human Services give employers more leeway to withhold birth control coverage on religious grounds.
Researchers at the University of Nottingham in England have found evidence that being in a positive mood when receiving an influenza (flu) vaccine can increase its protective effect.
